Hervé Hoppenot, Incyte CEO (Jeff Rumans)

In­cyte cuts fi­nal tri­al for PI3K drug more than a year af­ter yank­ing ac­cel­er­at­ed ap­proval fil­ing

The “chal­leng­ing reg­u­la­to­ry land­scape” sur­round­ing the class of drugs known as PI3K in­hibitors has pushed In­cyte to shut down the fi­nal tri­al in its PI3K …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.